Basilea Pharmaceutica Gross Profit vs. Price To Earning

Based on the key profitability measurements obtained from Basilea Pharmaceutica's financial statements, Basilea Pharmaceutica AG may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Basilea Pharmaceutica's ability to earn profits and add value for shareholders.
For Basilea Pharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Basilea Pharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Basilea Pharmaceutica AG utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Basilea Pharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Basilea Pharmaceutica AG over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Please note, there is a significant difference between Basilea Pharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Basilea Pharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Basilea Pharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Basilea Pharmaceutica Price To Earning vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Basilea Pharmaceutica's current stock value. Our valuation model uses many indicators to compare Basilea Pharmaceutica value to that of its competitors to determine the firm's financial worth.
Basilea Pharmaceutica AG is number one stock in gross profit category among its peers. It also is number one stock in price to earning category among its peers . The ratio of Gross Profit to Price To Earning for Basilea Pharmaceutica AG is about  161,845 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Basilea Pharmaceutica's earnings, one of the primary drivers of an investment's value.

Basilea Price To Earning vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Basilea Pharmaceutica

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
30.89 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Basilea Pharmaceutica

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
190.88 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Basilea Price To Earning Comparison

Basilea Pharmaceutica is currently under evaluation in price to earning category among its peers.

Basilea Pharmaceutica Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Basilea Pharmaceutica, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Basilea Pharmaceutica will eventually generate negative long term returns. The profitability progress is the general direction of Basilea Pharmaceutica's change in net profit over the period of time. It can combine multiple indicators of Basilea Pharmaceutica, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA N operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange. It employs 160 people.

Basilea Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Basilea Pharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Basilea Pharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Basilea Pharmaceutica's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Basilea Pharmaceutica without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sign In To Macroaxis Now

   

Sign In To Macroaxis

Sign in to explore Macroaxis' wealth optimization platform and fintech modules
All  Next Launch Module

Use Investing Themes to Complement your Basilea Pharmaceutica position

In addition to having Basilea Pharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Utilities Thematic Idea Now

Utilities
Utilities Theme
Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. The Utilities theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Basilea Stock Analysis

When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.